Viking Therapeutics, Inc. (VKTX)
Company Info
Highlights
$3.30B
-$1.16
-0.03
-$162.00K
-$172.21M
$18.92 - $81.73
$90.26
27.21%
6.02
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Viking Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Viking Therapeutics, Inc. (VKTX) returned -31.54% year-to-date (YTD) and -65.65% over the past 12 months. Over the past 10 years, VKTX delivered an annualized return of 11.87%, outperforming the S&P 500 benchmark at 10.45%.
VKTX
-31.54%
19.26%
-59.77%
-65.65%
33.50%
11.87%
^GSPC (Benchmark)
-3.77%
3.72%
-5.60%
8.55%
14.11%
10.45%
Monthly Returns
The table below presents the monthly returns of VKTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -18.61% | -11.85% | -16.35% | 19.54% | -4.57% | -31.54% | |||||||
| 2024 | 29.72% | 219.18% | 6.42% | -2.95% | -21.76% | -14.86% | 7.53% | 12.49% | -1.26% | 14.58% | -27.02% | -23.99% | 116.23% |
| 2023 | -6.81% | 25.68% | 51.23% | 27.99% | 3.05% | -26.18% | -10.55% | -4.76% | -19.84% | -11.38% | 24.57% | 52.29% | 97.98% |
| 2022 | -19.35% | -9.70% | -10.45% | -20.67% | -6.72% | 30.18% | 4.15% | 5.65% | -14.47% | 50.74% | -1.22% | 132.10% | 104.35% |
| 2021 | 29.84% | -7.80% | -6.16% | 1.03% | -18.00% | 14.31% | 2.67% | 7.48% | -4.99% | -7.32% | -8.76% | -13.37% | -18.29% |
| 2020 | -21.70% | -5.73% | -20.95% | 23.08% | 24.13% | 0.84% | -2.64% | -4.70% | -13.00% | -3.26% | 14.21% | -12.44% | -29.80% |
| 2019 | 6.67% | 3.06% | 18.19% | -21.23% | -1.79% | 7.93% | -7.35% | -9.62% | -1.01% | -5.96% | 13.14% | 9.56% | 4.84% |
| 2018 | 30.79% | 17.89% | -30.19% | -5.72% | 142.48% | -5.01% | 7.48% | 28.14% | 33.28% | -21.93% | -16.99% | -32.24% | 88.42% |
| 2017 | 18.49% | 8.51% | -4.58% | -4.11% | -15.71% | -8.47% | -2.78% | -0.95% | 83.65% | 24.61% | 27.73% | 33.55% | 241.18% |
| 2016 | -39.00% | -12.98% | -21.55% | 2.11% | -4.83% | -8.70% | 11.11% | -4.29% | 4.56% | -23.63% | 0.93% | 10.19% | -65.10% |
| 2015 | -1.79% | -6.48% | -13.24% | -14.71% | 0.99% | -4.72% | -3.75% | -43.26% | 6.56% | -61.94% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of VKTX is 9, meaning it’s performing worse than 91% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Viking Therapeutics, Inc. (VKTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Viking Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Viking Therapeutics, Inc. was 90.41%, occurring on Aug 2, 2017. Recovery took 208 trading sessions.
The current Viking Therapeutics, Inc. drawdown is 70.85%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -90.41% | May 7, 2015 | 565 | Aug 2, 2017 | 208 | May 31, 2018 | 773 |
| -89.26% | Sep 20, 2018 | 942 | Jun 16, 2022 | 209 | Apr 18, 2023 | 1151 |
| -78.86% | Feb 29, 2024 | 278 | Apr 8, 2025 | — | — | — |
| -62.73% | Jun 9, 2023 | 98 | Oct 27, 2023 | 70 | Feb 8, 2024 | 168 |
| -25.51% | Jun 18, 2018 | 10 | Jun 29, 2018 | 43 | Aug 30, 2018 | 53 |
Volatility
Volatility Chart
The current Viking Therapeutics, Inc. volatility is 21.06%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Viking Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Viking Therapeutics, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -31.7%.
Valuation
The Valuation section provides an overview of how Viking Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for VKTX compared to other companies in the Biotechnology industry. VKTX currently has a PEG ratio of -0.0. This PEG ratio is negative, which typically signals that the company's earnings are expected to decline. A negative PEG is not considered meaningful for valuation purposes.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for VKTX relative to other companies in the Biotechnology industry. Currently, VKTX has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for VKTX in comparison with other companies in the Biotechnology industry. Currently, VKTX has a P/B value of 3.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |